Diem Nguyen, Ph.D., M.B.A. is Chief Executive Officer and Director at SIGA. She was appointed in January 2024. Most recently, Dr. Nguyen served as CEO of Xalud Therapeutics, a clinical stage biotechnology company developing treatments for inflammatory diseases.

Diem Nguyen is Chief Executive Officer and Director at SIGA. She was appointed in January 2024. Most recently, Dr. Nguyen served as CEO of Xalud Therapeutics, a clinical stage biotechnology company developing treatments for inflammatory diseases.

2024年1月22日 · SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen , Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024 , and will also be appointed to the Company’s Board of Directors.

2024年1月22日 · As CEO, Dr. Nguyen will lead SIGA’s ongoing efforts in the development, manufacture and global distribution of antiviral therapies for the treatment of infectious diseases including smallpox ...

NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company’s Board of ...

Diem Nguyen has more than 25 years of experience and extensive expertise in the pharmaceutical industry. She is currently the CEO of SIGA Technologies, a public commercial stage pharmaceutical company focused on anti-viral treatments.

2024年1月23日 · Siga Technologies Inc. (NASDAQ:SIGA) named Die m Nguyen to succeed Phil Gomez as CEO, effective Jan. 27. Nguyen was CEO of Xalud Therapeutics Inc. and served as EVP of biopharma at PPD Inc.; Gomez is retiring on Jan. 26.

2025年1月2日 · SIGA Technologies has announced the appointment of Dr. Diem Nguyen as its new CEO, effective January 27, 2024, marking a leadership transition as Dr. Phil Gomez retires from the position. Dr. Nguyen's arrival presents an opportunity for SIGA to rejuvenate its financial performance and strengthen its position within the healthcare sector.

Diem Nguyen, Ph.D., is the CEO of SIGA Technologies, Inc., a biopharmaceutical company focused on developing treatments for serious infectious diseases. Dr. Nguyen s leadership is characterized by a focus on scientific innovation, research excellence, and strategic growth.

SIGA Technologies' CEO is Diem Nguyen, appointed in Jan 2024, has a tenure of 1.17 years. directly owns 0.095% of the company’s shares, worth $398.46K. The average tenure of the management team and the board of directors is 7.6 years and 3.8 years respectively.